Marie-Capucine W.
- Country
- France
- Department
- 2309: Service de Pneumologie
Research Overview
- Phase III Randomized Controlled Trial of Pembrolizumab with Platinum-Based Chemotherapy Versus Pembrolizumab Monotherapy in First-Line Treatment of NSCLC with PD-L1 ≥50%
- A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 antibody) in Combination with Cemiplimab (Anti-PD-1 antibody) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 ≥50%
- Phase III Study of Datopotamab Deruxtecan ± Osimertinib vs. Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC Post-Osimertinib Progression
Data & Insights
Has run more than one trial at 33 of 157 partner sites.
Specializations
Advanced Lung Cancer Management
The investigator specializes in treating advanced non-small cell lung cancer (NSCLC), with particular emphasis on developing therapeutic strategies for patients with progressive disease states.
- First-line Treatment Approaches
- Stage IIIB/IV NSCLC Management
- Locally Advanced Unresectable Disease
Focuses on therapeutic interventions for patients with specific biomarker profiles and disease characteristics.
Immunotherapy Innovation
Explores novel immunotherapeutic combinations and treatment strategies, particularly investigating immune checkpoint inhibitors in various NSCLC contexts.
- Combination Immunotherapy Approaches
- PD-L1 Expression Analysis
- Monotherapy vs Combination Strategies
Evaluates therapeutic outcomes in patients with specific PD-L1 expression levels.
Targeted Therapy Development
Investigates precision medicine approaches for NSCLC patients, focusing on specific molecular alterations and biomarker-driven treatments.
- EGFR Mutation Treatment
- ALK Rearrangement Therapy
- Post-Targeted Therapy Options
Specializes in developing treatment strategies for patients who have progressed after targeted therapies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.